F2R
Proteinase-activated receptor 1
As of the edition of 20 October 2026, F2R (proteinase-activated receptor 1, UniProt P25116) has 3 drugs tested at it and 2 companies on the list, 1 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P25116
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 13
- Disease areas
- Heart and blood vessels; Nervous system; Hormones; Infections; Nutrition and metabolism
- Registered trials of its drugs
- 19
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Went quiet | 2 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Vorapaxar | Marketed | Phase 4 | Ends 2027 |
| Atopaxar | Went quiet | Phase 2 | none listed |
| PZ-128 | Went quiet | Phase 2 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 1 |
| Total on the list | 2 |
| Company | Route |
|---|---|
| Merck & Co. | Route B |
| Eisai | Route A |
The other 0 companies at F2R
In the product2 companies in all; 0 are not named here, and no score is.
See the 2 companies at F2R, ranked, with the facts behind eachRequest access. Nothing is shown until you do.